SLN.L Regulatory News (SLN)

Results of General Meeting

London, 23rd July 2020

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that at its General Meeting held today, Thursday, 23rd July 2020, all resolutions set out in the notice of meeting were duly passed on a poll.

The votes were as follows:

The number of the Company's ordinary shares in issue as at the date of the meeting was 82,826,259 ordinary shares of 5p each.

A vote withheld is not a vote in law and has not been counted in the calculation of the proportion of votes for and against the resolutions.

Enquiries:

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/